Development and Preliminary Clinical Application of Circulating Tumor Cell Detection System for Prostate Cancer

Cao, Chengsong; Wang, Qun; Li, Qing; Zhao, Qingqing; Wang, Jun Qi; Liu, Yong

doi:10.1166/jbn.2019.2706

Cited by 4 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Multiparametric MRI has recently been established in our hospital and we also aim to implement it in the prospective validation of our models. In particular, the value of EPCAM and PSGR urinary transcripts deserves further analysis as they have so far been reported only in few studies [ 17 , 21 , 36 ].…”

Section: Discussionmentioning

confidence: 99%

“…There are also no urine-based studies for Ki67 ( MKI67 , marker of proliferation Ki67 ). Two studies have reported promising results for cancer detection using PSGR (prostate-specific G-protein coupled receptor, official gene name OR51E2 , olfactory receptor 51E2 ) [ 17 , 21 ]. We have also included PA2G4 which acts as an androgen receptor corepressor and may be downregulated in prostate cancer [ 22 ].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The Percentage of Free PSA and Urinary Markers Distinguish Prostate Cancer from Benign Hyperplasia and Contribute to a More Accurate Indication for Prostate Biopsy

et al. 2020

View full text Add to dashboard Cite

The main advantage of urinary biomarkers is their noninvasive character and the ability to detect multifocal prostate cancer (CaP). We have previously implemented a quadruplex assay of urinary markers into clinical practice (PCA3, AMACR, TRPM8 and MSMB with KLK3 normalization). In this study, we aimed to validate it in a larger cohort with serum PSA 2.5–10 ng/mL and test other selected transcripts and clinical parameters, including the percentage of free prostate-specific antigen (PSA) (% free PSA) and inflammation. In the main cohort of 299 men, we tested the quadruplex transcripts. In a subset of 146 men, we analyzed additional transcripts (CD45, EPCAM, EZH2, Ki67, PA2G4, PSGR, RHOA and TBP). After a prostate massage, the urine was collected, RNA isolated from a cell sediment and qRT-PCR performed. Ct values of KLK3 (i.e., PSA) were strongly correlated with Ct values of other genes which play a role in CaP (i.e., PCA3, AMACR, TRPM8, MSMB and PSGR). AMACR, PCA3, TRPM8 and EZH2 mRNA expression, as well as % free PSA, were significantly different for BPH and CaP. The best combined model (% free PSA plus PCA3 and AMACR) achieved an AUC of 0.728 in the main cohort. In the subset of patients, the best AUC 0.753 was achieved for the combination of PCA3, % free PSA, EPCAM and PSGR. PCA3 mRNA was increased in patients with inflammation, however, this did not affect the stratification of patients indicated for prostate biopsy. In conclusion, the percentage of free PSA and urinary markers contribute to a more accurate indication for prostate biopsy.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

The Percentage of Free PSA and Urinary Markers Distinguish Prostate Cancer from Benign Hyperplasia and Contribute to a More Accurate Indication for Prostate Biopsy

et al. 2020

View full text Add to dashboard Cite

show abstract

Nurturing the marriages of urinary liquid biopsies and nano‐diagnostics for precision urinalysis of prostate cancer

Liao

Chen

et al. 2023

Smart Medicine

View full text Add to dashboard Cite

Prostate cancer remains the second-most common cancer diagnosed in men, despite the increasingly widespread use of serum prostate-specific antigen (PSA) screening. The controversial clinical implications and cost benefits of PSA screening have been highlighted due to its poor specificity, resulting in a high rate of overdiagnosis and underdiagnosis. Thus, the development of novel biomarkers for prostate cancer detection remains an intriguing challenge. Urine is emerging as a source for prostate cancer biomarker discovery.Currently, new urine biomarkers already outperform serum PSA in clinical diagnosis. Meanwhile, the advances in nanotechnology have provided a suite of diagnostic tools to study prostate cancer in more detail, sparking a new era of biomarker discoveries. In this review, we envision that future prostate cancer diagnosis will probably integrate multiplex nano-diagnostic approaches to detect novel urinary biomarkers. However, challenges remain in differentiating indolent from aggressive cancers to better inform treatment decisions, and clinical translation still needs to be overcome.This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

show abstract

Molecular biomarkers in prostate cancer tumorigenesis and clinical relevance

Alqualo,

Campos-Fernandez,

Picolo

et al. 2024

Critical Reviews in Oncology/Hematology

View full text Add to dashboard Cite

Development and Preliminary Clinical Application of Circulating Tumor Cell Detection System for Prostate Cancer

Cited by 4 publications

References 0 publications

The Percentage of Free PSA and Urinary Markers Distinguish Prostate Cancer from Benign Hyperplasia and Contribute to a More Accurate Indication for Prostate Biopsy

The Percentage of Free PSA and Urinary Markers Distinguish Prostate Cancer from Benign Hyperplasia and Contribute to a More Accurate Indication for Prostate Biopsy

Nurturing the marriages of urinary liquid biopsies and nano‐diagnostics for precision urinalysis of prostate cancer

Molecular biomarkers in prostate cancer tumorigenesis and clinical relevance

Contact Info

Product

Resources

About